Five things for pharma marketers to know: Wednesday, August 30, 2017

Share this content:


1. A group of nonprofits and the Chemo Group have received FDA approval for a drug that treats Chagas disease. In late 2015 the then KaloBios Pharmaceuticals CEO, Martin Shkreli, was criticized for buying a benznidazole, a longtime treatment for Chagas disease, and then announcing plans to raise the price from between $50 and $100 for a course a treatment to $60,000 to $90,000. (Endpoints News)

2. Gilead Sciences' proposed acquisition of Kite Pharma will put the drugmaker back in the center of the debate around drug prices. If approved, Kite's experimental CAR-T therapy will likely cost between $300,000 to $500,000. (WaPo)

3. About half of cancer patients of reproductive age do not receive enough information about how treatment can affect their fertility, a new study found. A cancer diagnosis and treatment can temporarily or permanently affect the fertility of up to 75% of people who survive. (Reuters)

4. It's unclear whether pharma executives will support the FDA's proposal to shorten the list of side effects often listed at the end of DTC ads, but it's likely that they will. (Forbes)

5. Young women who are religious know less about the HPV vaccine than women who don't practice a religion, a new study found. They are also less likely to have received at least one dose of the HPV vaccine. (Reuters)

Share this content:
Scroll down to see the next article